Biogen vs Royalty Pharma
Biogen (BIIB), health care, and Royalty Pharma (RPRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Royalty Pharma is worth $39.5B on the stock market and Biogen $37.1B: Royalty Pharma is valued at 7% more. Biogen trades at 109 times earnings and Royalty Pharma at 44.9. Over the past year Biogen's share price has moved +49.1% and Royalty Pharma's +73.7%.
Key facts
- Biogen market value
- $37.1B
- Royalty Pharma market value
- $39.5B
- Biogen P/E
- 109
- Royalty Pharma P/E
- 44.9
- Biogen revenue
- $9.9BFY to 2025-12-31
- Royalty Pharma revenue
- $2.4BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Biogen | Royalty Pharma |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $37.1Blower | $39.5Bhigher |
| Revenue | $9.9Bhigher | $2.4Blower |
| Earnings | $1.3Bhigher | $770.9Mlower |
| Employees | 7,500higher | 100lower |
| Total assets | $29.4Bhigher | $19.6Blower |
| Valuation | ||
| P/E | 109higher | 44.9lower |
| P/S | 3.7lower | 16.6higher |
| P/B | 2.0lower | 4.5higher |
| Dividend yield | 0.00%lower | 1.35%higher |
| Profitability | ||
| Operating margin | — | 65.6% |
| Balance sheet | ||
| Net assets | $18.3Bhigher | $9.7Blower |
| Total liabilities | $11.2Bhigher | $9.9Blower |
| Total debt | $6.3Blower | $9Bhigher |
| Cash on hand | $3Bhigher | $618.7Mlower |
| Price change | ||
| Today | -0.34%lower | +0.23%higher |
| 1 year | +49.1%lower | +73.7%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Samantha McLemore1.9% / 6.7%
Biogen only (3)
- Primecap team2.1%
- Andrew Spokes0.8%
- Joel Greenblatt0.1%
Royalty Pharma only (4)
- Pat Dorsey8.2%
- Baillie Gifford team0.5%
- Murray Stahl0.3%
- Paul Tudor Jones0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Biogen / Royalty Pharma). Who owns BIIB · Who owns RPRX
More on Biogen
Further comparisons
Biogen against its closest peers
Royalty Pharma against its closest peers
Learn
Questions and answers
Which is bigger, Biogen or Royalty Pharma?
By market value, Royalty Pharma is the larger: $39.5B against $37.1B for Biogen. By revenue in its latest fiscal year, Biogen is the larger: $9.9B against $2.4B for Royalty Pharma.
Which has the higher P/E ratio?
Biogen: 109, against 44.9 for Royalty Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
Royalty Pharma: 1.35%, against 0.00% for Biogen. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Royalty Pharma: $9B, against $6.3B for Biogen. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Biogen and Royalty Pharma?
In their latest 13F filings, Samantha McLemore holds both.
Cite this page
Funkfolio, “Biogen vs Royalty Pharma”, data as of 18 November 2026. https://funkfolio.com/compare/biib-vs-rprx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.